Breakthrough Cancer Pain
14
0
0
7
Key Insights
Highlights
Success Rate
78% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
14.3%
2 terminated out of 14 trials
77.8%
-8.7% vs benchmark
7%
1 trials in Phase 3/4
14%
1 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (14)
Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP
Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer Patients
Treatment of Breakthrough Cancer Pain According to European Guidelines
Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain
Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Breakthrough Cancer Pain
Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain
A Dose Titration Study of Fentanyl Buccal Soluble Film for Breakthrough Cancer Pain in Taiwan
Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain
Observational Registry Study of Quality of Life When Treating BTcP With Abstral
Patient Satisfaction and Quality of Life Impact - PecFent®
Patient Satisfaction and Quality of Life Impact - PecFent®
A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain
Instanyl® Non-Interventional Study
Safety of Fentanyl TAIFUN Treatment